A 9-amino-acid synthetic analog of gonadotropin-releasing hormone (GnRH) with a D-leucine substitution that makes it 80x more potent than natural GnRH. Used to treat prostate cancer, endometriosis, uterine fibroids, and precocious puberty through paradoxical receptor downregulation.
Leuprolide (leuprorelin) is a 9-amino-acid synthetic analog of gonadotropin-releasing hormone (GnRH). It contains a key modification: replacement of Gly10 with D-Leu-NHEt at the C-terminus, which makes it resistant to enzymatic degradation and approximately 80 times more potent than native GnRH.
Leuprolide works through a paradoxical mechanism: initially it stimulates the pituitary to release LH and FSH (a 'flare' effect), but with continuous administration, it causes GnRH receptor downregulation and desensitization, ultimately suppressing LH/FSH to castrate levels. This effectively shuts down gonadal steroid production (testosterone in men, estrogen in women).
Leuprolide exploits the difference between pulsatile vs continuous GnRH receptor activation. The hypothalamus normally releases GnRH in pulses, and each pulse triggers a burst of LH/FSH release from the pituitary. This pulsatile pattern is essential — without it, the GnRH receptors are internalized, degraded, and not replaced. Leuprolide provides constant receptor stimulation, driving continuous internalization until the pituitary gonadotrophs are essentially 'deaf' to GnRH signaling.
| Pathway | Effect | Significance |
|---|---|---|
| Initial flare | Super-agonism causes LH/FSH surge for 1-2 weeks | Must be managed in prostate cancer (can worsen symptoms temporarily) |
| Receptor downregulation | Continuous stimulation → receptor internalization and degradation | Pituitary gonadotrophs lose GnRH responsiveness |
| Chemical castration | LH/FSH fall to castrate levels → testosterone/estrogen suppressed | Equivalent to surgical castration but reversible |
| D-Leu substitution | Prevents carboxypeptidase degradation at C-terminus | 80x potency increase + extended duration |
| Depot formulations | Microsphere or gel technology for sustained release | Monthly, quarterly, or 6-month injections available |
| Study | Design | Findings | Level |
|---|---|---|---|
| Prostate cancer | Extensive RCTs, standard of care | Suppresses testosterone to castrate levels. First-line androgen deprivation therapy for advanced prostate cancer. | Level I |
| Endometriosis | Multiple RCTs | Suppresses estrogen, reducing endometrial implant growth and pain. FDA-approved indication. | Level I |
| Uterine fibroids | RCTs | Pre-surgical shrinkage of fibroids by estrogen suppression. Approved for preoperative use. | Level I |
| Precocious puberty | Clinical standard | Suppresses premature activation of the HPG axis. FDA-approved for central precocious puberty. | Level I |
| IVF protocols | Standard practice | Used in controlled ovarian stimulation to prevent premature LH surge | Level I |
Initial flare: In prostate cancer, the initial testosterone surge can worsen bone pain and urinary symptoms. Managed with anti-androgens (flutamide, bicalutamide) during the first 2-4 weeks.
Bone density loss: Long-term sex hormone suppression causes bone mineral density loss. Calcium, vitamin D, and monitoring recommended.
Hot flashes: Very common (>80%) due to hormone suppression. Same mechanism as menopausal hot flashes.
Mood changes: Depression, mood swings, decreased libido are common with sustained hormone suppression.
Cardiovascular risk: Long-term androgen deprivation may increase cardiovascular risk. Monitoring recommended.
| Jurisdiction | Status |
|---|---|
| FDA | Approved: Lupron/Lupron Depot for prostate cancer, endometriosis, uterine fibroids, precocious puberty, IVF |
| Generic | Multiple generic formulations available |
| Clinical significance | One of the most versatile peptide drugs — used across oncology, gynecology, pediatrics, and reproductive medicine |